Rexulti 0.25mg film-coated tablets

Manufacturer
Otsuka Pharmaceutical Co., Ltd(JAPAN)

Registraction Number
MAL20026042ARZ

Content:

• Active Ingredient: Brexpiprazole 0.25 mg

• Treat major depressive disorder (MDD) as an adjunctive therapy to antidepressants.
• Treat schizophrenia in adults and adolescents aged 13 years and older.
• Treat agitation associated with Alzheimer’s dementia.

• Dosage: The starting dose for MDD is 0.5 mg or 1 mg once daily, with a recommended dose of up to 2 mg per day. For schizophrenia, the starting dose is 1 mg once daily, with a recommended dose of 2 to 4 mg per day. For patients with moderate to severe hepatic impairment or moderate to severe renal impairment, the maximum recommended dose is lower.
• Administration: Take Rexulti once daily with or without food. Swallow the tablet whole with water.
• Precautions: Inform your doctor if you have any allergies, liver or kidney problems, or if you are pregnant or planning to become pregnant. Regular monitoring of blood counts and liver function is necessary during treatment.
• Storage: Store at room temperature, away from moisture and heat.